{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_005678.3:c.6056G>T (p.G2019S)",
          "cDNA Change": {
            "transcript": "NM_005678.3",
            "ref": "G",
            "alt": "T",
            "position": "6056"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "c.6056G>T (p.G2019S)"
        },
        {
          "HGVS": "NM_005678.3:c.6059T>A (p.I2020T)",
          "cDNA Change": {
            "transcript": "NM_005678.3",
            "ref": "T",
            "alt": "A",
            "position": "6059"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "c.6059T>A (p.I2020T)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease, late-onset autosomal dominant",
    "MONDO": "MONDO:0018945"
  },
  "Experiment Method": [
    {
      "Assay Method": "Binding assay and enzymatic activity assay",
      "Material used": {
        "Material Source": "Recombinant proteins or cell lines expressing the mutants",
        "Material Name": "LRRK2-G2019S, LRRK2-I2020T",
        "Description": "The experiments were conducted using recombinant LRRK2 proteins or cell lines expressing the G2019S and I2020T mutants."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_005678.3:c.6056G>T (p.G2019S)",
          "Conclusion": "Altered ATP affinity and increased sensitivity to inhibitors",
          "Molecular Effect": "Gain-of-function mutation leading to increased kinase activity",
          "Result Description": "The G2019S mutant showed a 2-fold decrease in ATP affinity compared to wild-type LRRK2. Additionally, it exhibited a 6-fold increase in sensitivity to kinase inhibitors."
        },
        {
          "Variant": "NM_005678.3:c.6059T>A (p.I2020T)",
          "Conclusion": "Altered ATP affinity and increased resistance to inhibitors",
          "Molecular Effect": "Partial loss-of-function mutation with altered substrate binding",
          "Result Description": "The I2020T mutant exhibited a 6-fold increase in ATP affinity compared to wild-type LRRK2. It also showed a 10-fold increase in resistance to kinase inhibitors."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not described in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not described in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not described in the literature."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not described in the literature."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Not described in the literature. Standard thresholds for ATP affinity and kinase activity would typically be based on wild-type values.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Not described in the literature. Abnormal thresholds would typically be deviations from wild-type values, such as significant increases or decreases in ATP affinity or kinase activity.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes",
        "Description": "Binding assays and enzymatic activity assays are standard methods for studying kinase activity and ATP binding in the context of Parkinson's disease research."
      }
    }
  ]
}